Our previous studies have discovered new stress protein families, i.e. the hsp110 and grpl70 families, and we have characterized their molecular chaperone functions. We have shown that both hsp110 and grpl70 are highly efficient in binding to and stabilizing substrate proteins during heat shock. In the present application we use this new knowledge to formulate novel cancer vaccines by replacing the reporter proteins used in our earlier studies with a major tumor protein antigen, her-2/neu. Chaperone complexes between hsp 110 or grp 170 and the intracellular or extracellular domains of her-2/neu are formed by heat shock. These chaperone complexes are then tested for vaccine activity. Ovalbumin, a well-characterized model antigen, is then used in complex with hsp110 or grpl70 for mechanistic studies to understand how vaccine activity is obtained.
In Aim 1 we will determine whether the natural chaperone complexes between the intracellular or extracellular domains of her-2/neu and hsp110 or grp 170 have anti-tumor activity in mice. This will utilize a spontaneous her-2-neu expressing mouse transgenic model, which closely mimics the human disease.
In Aim 2, we will investigate the mechanisms by which these vaccines function using a well characterized model system, the Ovalbumin system.
This aim will investigate receptor binding of hspll0- and grpl70- Ova complexes, their uptake and processing in dendritic cells.
Aim 3 will determine whether hsp110 and grp 170 can function to mature dendritic cells necessary for antigen presentation and determine if this occurs via an NF-kB pathway. Finally, Aim 4 will determine the functional domains of hsp110 and grpl70 involved in their immunological activities defined in the first three aims. These studies will define the mechanisms of action of targeted, natural chaperone complexes of recombinant heat shock proteins with a major protein antigen as cancer vaccines. The characterization of these hsp-protein vaccines and how they function can be expected to define new strategies for the use of hsp-vaccine therapy and to have immediate clinical application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
9R01CA099326-12
Application #
6573635
Study Section
Radiation Study Section (RAD)
Program Officer
Wong, Rosemary S
Project Start
1992-02-18
Project End
2008-01-31
Budget Start
2003-02-20
Budget End
2004-01-31
Support Year
12
Fiscal Year
2003
Total Cost
$377,046
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Ma, Yibao; Temkin, Sarah M; Hawkridge, Adam M et al. (2018) Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. Cancer Lett 435:92-100
Menezes, Mitchell E; Bhoopathi, Praveen; Pradhan, Anjan K et al. (2018) Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases. Adv Cancer Res 138:143-182
Payne, Kyle K; Aqbi, Hussein F; Butler, Savannah E et al. (2018) Gr1-/low CD11b-/low MHCII+ myeloid cells boost T cell anti-tumor efficacy. J Leukoc Biol 104:1215-1228
Emdad, Luni; Das, Swadesh K; Wang, Xiang-Yang et al. (2018) Cancer terminator viruses (CTV): A better solution for viral-based therapy of cancer. J Cell Physiol 233:5684-5695
Guo, Chunqing; Subjeck, John R; Wang, Xiang-Yang (2018) Creation of Recombinant Chaperone Vaccine Using Large Heat Shock Protein for Antigen-Targeted Cancer Immunotherapy. Methods Mol Biol 1709:345-357
Tang, Yuan; Li, Huifang; Li, Junru et al. (2017) Macrophage scavenger receptor 1 contributes to pathogenesis of fulminant hepatitis via neutrophil-mediated complement activation. J Hepatol :
Bucsek, Mark J; Qiao, Guanxi; MacDonald, Cameron R et al. (2017) ?-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy. Cancer Res 77:5639-5651
Pagare, Piyusha P; Zaidi, Saheem A; Zhang, Xiaomei et al. (2017) Understanding molecular interactions between scavenger receptor A and its natural product inhibitors through molecular modeling studies. J Mol Graph Model 77:189-199
PrabhuDas, Mercy R; Baldwin, Cynthia L; Bollyky, Paul L et al. (2017) A Consensus Definitive Classification of Scavenger Receptors and Their Roles in Health and Disease. J Immunol 198:3775-3789
Zheng, Yi; Li, Xia; Pagare, Piyusha P et al. (2017) Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A. Bioorg Med Chem Lett 27:72-76

Showing the most recent 10 out of 43 publications